Outcomes after photodynamic therapy of basalcell carcinoma on the eyelid skin with intravenous administration of photosensitizer chloride E6

Purpose. To evaluate immediate and long-term outcomes after photodynamic therapy (PDT) of basal cell carcinoma (BCC) on the eyelid with intravenous administration of photosensitizer (PS) chlorine E6.Materials and methods. PDT was performed in 261 patients with a verified diagnosis of BCC of the eyelid cT1-3N0MO, stage I–II, aged 38 to 87 (average 68.7 ± 15.6). PS chlorin E6 (Photolon, Photoditazin, Radachlorin) was used intravenously at dosage 1.0–1.5mg/kg; 1–2 courses. Light dosage ranged from 100 to 300 J/cm2, depending on the neoplasm clinical form and the data of fluorescence diagnostics.Results. Complete regression after the first PDT course of eyelid BCC cT1-3N0M0 with intravenous administration of PS chlorin E6 was obtained in 90.4 % of cases; after 2 courses - in 96.2 % of cases. During the follow-up period from 5 to 15 years, relapses were diagnosed in 7.6 % of cases. The number of relapses depended on the process stage. In neoplasms corresponding to the symbol cT1a, the number of relapses was 1.4 %, cT1 b – 5.0 %, cT1 c– 8.3 %, cT2 a – 2.5 %, cT2 b – 5.0 %, cT2 c – 9 %, cT3 a – 5.8 %, cT3 b – 43.8 %, cT3 c – 46.7 %. Good and excellent cosmetic results were seen too.Conclusion. PDT of eyelid BCC of stage I–II with intravenous administration of PS chlorine E6 is an effective and low-risk method for anatomical and functional disorders. It can be an alternativetechnique to surgical treatment. The discussed way of treatment should be personalized and provided in specialized medical settings.